Posted by Michael Wonder on 19 Jun 2025
Tislelizumab for the treatment of adults with advanced non-small-cell lung cancer after platinum-based chemotherapy
19 June 2025 - NICE is unable to make a recommendation on the use of tislelizumab (Tevimbra) for the treatment of adults with advanced non-small-cell lung cancer after platinum-based chemotherapy because BeiGene withdrew its evidence submission.
NICE will review this decision if BeiGene decides to make a submission.
